Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
3.630
-0.210 (-5.47%)
At close: Oct 9, 2026, 4:00 PM EDT
3.550
-0.080 (-2.20%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Immutep Revenue
In the fiscal year ending June 30, 2026, Immutep had annual revenue of 14.60M AUD with 24,344.44% growth. Immutep had revenue of 10.50M in the half year ending June 30, 2026, with 34,682.21% growth.
Revenue (ttm)
14.60M AUD
Revenue Growth
+24,344.44%
P/S Ratio
1.94
Revenue / Employee
470,824 AUD
Employees
31
Market Cap
26.74M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 14.60M | 14.54M | 24,344.44% |
| Jun 30, 2025 | 59.71K | -59.38K | -49.86% |
| Jun 30, 2024 | 119.09K | -72.63K | -37.88% |
| Jun 30, 2023 | 191.72K | -62.67K | -24.63% |
| Jun 30, 2022 | 254.39K | -58.45K | -18.68% |
| Jun 30, 2021 | 312.84K | -7.45M | -95.97% |
| Jun 30, 2020 | 7.77M | 6.47M | 499.78% |
| Jun 30, 2019 | 1.29M | -2.34M | -64.42% |
| Jun 30, 2018 | 3.64M | 2.84M | 354.63% |
| Jun 30, 2017 | 800.46K | 625.41K | 357.27% |
| Jun 30, 2016 | 175.05K | - | - |
| Jun 30, 2015 | - | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | - | - | - |
| Jun 30, 2006 | - | - | - |
| Jun 30, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Evaxion | 7.49M |
| Kyntra Bio | 4.62M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| aTyr Pharma | 190.00K |
IMMP News
- 8 days ago - Immutep Limited - Depositary Receipt Price Target Increased by 917.93% to $69.75 - Nasdaq
- 10 days ago - Immutep receives A$856,669 cash rebate from Australia R&D tax incentive program - TheFly
- 10 days ago - Immutep Receives ~A$0.86 Million R&D Tax Incentive - GlobeNewsWire
- 15 days ago - Immutep Ltd trading halted, news pending - TheFly
- 4 weeks ago - Immutep provides update on development strategy for eftilagimod alfa - TheFly
- 5 weeks ago - Immutep Annual report: H2 2026 - Filings
- 7 weeks ago - Immutep Slides: Corporate presentation - Filings
- 2 months ago - Immutep granted new patent for eftilagimod alfa combination - TheFly